Shufro Rose & Co. LLC lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 31.7% during the first quarter, Holdings Channel reports. The fund owned 830 shares of the biopharmaceutical company’s stock after acquiring an additional 200 shares during the quarter. Shufro Rose & Co. LLC’s holdings in Regeneron Pharmaceuticals were worth $393,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the stock. Norges Bank acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $506,839,000. Alliancebernstein L.P. grew its holdings in Regeneron Pharmaceuticals by 13.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,763,344 shares of the biopharmaceutical company’s stock valued at $851,889,000 after buying an additional 208,936 shares during the last quarter. Morgan Stanley grew its holdings in Regeneron Pharmaceuticals by 56.1% in the 4th quarter. Morgan Stanley now owns 547,337 shares of the biopharmaceutical company’s stock valued at $264,425,000 after buying an additional 196,601 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $75,487,000. Finally, Brandywine Global Investment Management LLC grew its holdings in Regeneron Pharmaceuticals by 673.8% in the 4th quarter. Brandywine Global Investment Management LLC now owns 123,966 shares of the biopharmaceutical company’s stock valued at $59,889,000 after buying an additional 107,945 shares during the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Shares of REGN stock opened at $488.62 on Tuesday. The stock’s fifty day simple moving average is $482.38 and its 200 day simple moving average is $503.31. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.89 and a quick ratio of 3.12. Regeneron Pharmaceuticals, Inc. has a one year low of $441.00 and a one year high of $664.64. The firm has a market cap of $52.35 billion, a price-to-earnings ratio of 17.86, a P/E/G ratio of 0.82 and a beta of 0.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, February 4th. The biopharmaceutical company reported $9.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $7.11 by $2.42. Regeneron Pharmaceuticals had a return on equity of 28.97% and a net margin of 38.28%. The firm had revenue of $2.42 billion during the quarter, compared to the consensus estimate of $2.40 billion. During the same quarter in the previous year, the company posted $7.50 EPS. The business’s revenue for the quarter was up 11.7% compared to the same quarter last year. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 27.23 earnings per share for the current year.

A number of research firms have issued reports on REGN. Canaccord Genuity reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 13th. FIX raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and decreased their price objective for the stock from $635.00 to $575.00 in a report on Friday, January 8th. Cantor Fitzgerald decreased their price objective on Regeneron Pharmaceuticals from $696.00 to $656.00 and set an “overweight” rating on the stock in a report on Tuesday, February 16th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lifted their price objective on Regeneron Pharmaceuticals from $575.00 to $584.00 and gave the stock a “buy” rating in a report on Thursday, January 14th. Finally, Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $590.00 price objective on the stock in a report on Wednesday, January 13th. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $644.17.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: Percentage Gainers

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.